Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
The understanding of the molecular mechanisms of neonatal diabetes has deeply changed the
therapy of patients carrying mutations in the K-ATP channel. Indeed, those patients are not
treated anymore by insulin injections but by glibenclamide an oral anti-diabetic drug widely
used in type 2 diabetes. Anyway, its galenic form (pills of 5 mg) is not suitable for
children and difficult to administrate to infants or young children. The purpose of this
study is to determine if a new galenic form of this durg is more suitable and as efficient as
pills in children with neonatal diabetes.